Literature DB >> 4044994

Derivation of a bioclinical prognostic index in severe head injury.

P Hans, A Albert, J D Born, J P Chapelle.   

Abstract

We investigated the problem of outcome prediction from seven risk factors in 40 severely head injured patients - 13 favorable and 27 unfavorable outcomes. By applying stepwise logistic discriminant analysis to the patients' data, we selected three significant risk variables: cerebrospinal fluid (CSF) CK-BB isoenzyme activity recorded on admission, severely raised intracranial pressure (more than 40 mmHg) and age, respectively. CSF CK-BB activity, which quantifies the initial neurological damage, proved to be the best prognostic factor. The presence of severe intracranial hypertension was always associated with a bad outcome, whereas its absence was not necessarily indicative of good prognosis. Finally, we combined the three selected variables into a single risk index, which allowed correct predictions in 92% of patients with favorable outcome and in 85% of patients with unfavorable outcome (total predictive efficiency 88%).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4044994     DOI: 10.1007/BF00272401

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  25 in total

1.  The outcome from severe head injury with early diagnosis and intensive management.

Authors:  D P Becker; J D Miller; J D Ward; R P Greenberg; H F Young; R Sakalas
Journal:  J Neurosurg       Date:  1977-10       Impact factor: 5.115

2.  Factors affecting the clinical corse of patients with severe head injuries. 1. Influence of biological factors. 2. Significance of posttraumatic coma.

Authors:  C A Carlsson; C von Essen; J Löfgren
Journal:  J Neurosurg       Date:  1968-09       Impact factor: 5.115

3.  The outcome with aggressive treatment in severe head injuries. Part I: the significance of intracranial pressure monitoring.

Authors:  L F Marshall; R W Smith; H M Shapiro
Journal:  J Neurosurg       Date:  1979-01       Impact factor: 5.115

4.  Statistical methods for determining prognosis in severe head injury.

Authors:  D M Stablein; J D Miller; S C Choi; D P Becker
Journal:  Neurosurgery       Date:  1980-03       Impact factor: 4.654

5.  Creatine kinase isoenzymes in severe head injury.

Authors:  P Hans; J D Born; J P Chapelle; G Milbouw
Journal:  J Neurosurg       Date:  1983-05       Impact factor: 5.115

6.  [Creatine kinase isoenzymes in severe head injury (author's transl)].

Authors:  P Hans; J D Born; J P Chapelle; G Milbouw
Journal:  Neurochirurgie       Date:  1982       Impact factor: 1.553

7.  [Practical assessment of brain dysfunction in severe head trauma (author's transl)].

Authors:  J D Born; P Hans; G Dexters; K Kalangu; J Lenelle; G Milbouw; A Stevenaert
Journal:  Neurochirurgie       Date:  1982       Impact factor: 1.553

8.  Outcome following severe head injuries in children.

Authors:  D A Bruce; L Schut; L A Bruno; J H Wood; L N Sutton
Journal:  J Neurosurg       Date:  1978-05       Impact factor: 5.115

9.  Further heterogeneity demonstrated for serum creatine kinase isoenzyme MM.

Authors:  J P Chapelle; C Heusghem
Journal:  Clin Chem       Date:  1980-03       Impact factor: 8.327

10.  The diagnostic value of measuring creatine kinase BB activity in cerebrospinal fluid following acute head injury.

Authors:  H K Nordby; P Urdal
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

View more
  3 in total

1.  Empirical Likelihood-Based Confidence Interval of ROC Curves.

Authors:  Haiyan Su; Yongsong Qin; Hua Liang
Journal:  Stat Biopharm Res       Date:  2009-11-01       Impact factor: 1.452

2.  Late post-concussional symptoms in traumatic head injury. An analysis of frequency and risk factors.

Authors:  T H Edna; J Cappelen
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

3.  Mixtures of receiver operating characteristic curves.

Authors:  Mithat Gönen
Journal:  Acad Radiol       Date:  2013-05-03       Impact factor: 3.173

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.